Your browser doesn't support javascript.
Evaluation of the BioFire® COVID-19 test and Respiratory Panel 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples.
Eckbo, Eric J; Locher, Kerstin; Caza, Melissa; Li, Lisa; Lavergne, Valery; Charles, Marthe.
  • Eckbo EJ; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada.
  • Locher K; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada.
  • Caza M; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada.
  • Li L; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada.
  • Lavergne V; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada.
  • Charles M; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Medical Microbiology & Infection Control & Control, Vancouver Coastal Health, Vancouver, BC, Canada. Electronic address: marthe.charles@vch.ca.
Diagn Microbiol Infect Dis ; 99(3): 115260, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1139480
ABSTRACT
The BioFire® COVID-19 Test and Respiratory Panel 2.1 (RP2.1) are rapid, fully automated assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs. In the case of the RP2.1, an additional 21 viral and bacterial pathogens can be detected. Both tests have received emergency use authorization from the U.S. Food & Drug Administration and Interim Order authorization from Health Canada for use in clinical laboratories. We evaluated the performance characteristics of these tests in comparison to a laboratory-developed real-time PCR assay targeting the viral RNA-dependent RNA polymerase and E genes. A total of 78 tests were performed using the BioFire COVID-19 Test, including 30 clinical specimens and 48 tests in a limit of detection study; 57 tests were performed using the RP2.1 for evaluation of SARS-CoV-2 detection, including 30 clinical specimens and 27 tests for limit of detection. Results showed 100% concordance between the BioFire assays and the laboratory-developed test for all clinical samples tested, and acceptable performance of both BioFire assays at their stated limits of detection. Conclusively, the BioFire COVID-19 Test and RP2.1 are highly sensitive assays that can be effectively used in the clinical laboratory for rapid SARS-CoV-2 testing.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nasopharynx / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article Affiliation country: J.diagmicrobio.2020.115260

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Nasopharynx / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article Affiliation country: J.diagmicrobio.2020.115260